10 Panel Drug Test Dip Cards

Ten-substance urine drug test dip cards screening Amphetamines, Buprenorphine, Benzodiazepines, Cocaine, MDMA, Methamphetamine, Methadone, Opiates, Oxycodone, and Marijuana in a single dip. The first tier in the dip card lineup to include MDMA as a dedicated analyte alongside the full prescription opioid triad of OXY, MTD, and BUP. CLIA Waived and FDA-cleared. From $0.99 per test. Same-day wholesale shipping before 3:00 PM EST.

Shop the 10 Panel Drug Test Dip Card — CLIA Waived — from $0.99 per test

What Is a 10 Panel Drug Test Dip Card and What Does It Detect?

A 10 panel drug test dip card is a urine immunoassay screening device that detects ten substances in a single dip — AMP, BUP, BZO, COC, MDMA, MET, MTD, OPI, OXY, and THC — with CLIA Waived FDA clearance and results in 5 minutes. At 12 Panel Now, the 10 Panel Drug Test Dip Card is the most analytically comprehensive CLIA Waived dip card available at the 10-substance tier, providing simultaneous detection of four opioid-class analytes (OPI, OXY, MTD, BUP) alongside MDMA, two stimulant analytes (AMP, MET), and the three sedative-cannabis analytes (BZO, COC, THC). As the manufacturer of the Serenity brand drug testing product line, 12 Panel Now produces the 10-panel dip card to the same quality standards applied across the full product range. According to the SAMHSA Drug-Free Workplace Program, the 10-panel substance set is the most commonly adopted expanded baseline in US drug testing programs outside federally mandated DOT formats.

Is MDMA on the 10 Panel Drug Test? What Is the MDMA Strip?

Yes — MDMA (3,4-Methylenedioxymethamphetamine, commonly known as Ecstasy or Molly) is on the 10 panel drug test dip card, and this is the lowest panel count at which MDMA has its own dedicated analyte in the dip card lineup. The 6-panel, 7-panel, and 8-panel dip cards do not include MDMA. The 10-panel adds an MDMA-specific strip at 500 ng/mL that uses antibodies targeting MDMA and its primary metabolite MDA (3,4-Methylenedioxyamphetamine) in urine. The AMP strip on lower panel counts does have some cross-reactivity with MDMA at very high concentrations, but this cross-reactivity is inconsistent and well below the threshold needed for reliable detection. A dedicated MDMA strip at 500 ng/mL is the only reliable way to screen for MDMA use at clinical concentrations in a rapid urine test. This matters because MDMA use patterns are distinct from amphetamine use patterns — MDMA is primarily used in recreational social settings including music festivals and nightlife rather than through the patterns of daily stimulant misuse associated with amphetamine and methamphetamine. Programs monitoring populations with documented MDMA use histories, or programs serving nightlife, entertainment, or healthcare worker demographics, should ensure their panel includes a dedicated MDMA strip rather than relying on AMP cross-reactivity. The NIH research on MDMA immunoassay cross-reactivity confirms that AMP-targeted strips are insufficient for reliable MDMA detection in clinical screening applications.

Does the 10 Panel Drug Test Dip Card Test for Buprenorphine, Oxycodone, and Methadone?

Yes. The 10 panel dip card includes dedicated strips for all three — Buprenorphine (BUP) at 10 ng/mL, Oxycodone (OXY) at 100 ng/mL, and Methadone (MTD) at 300 ng/mL — making it the most comprehensive opioid-coverage dip card available without moving to a 12-panel or higher format. This is what makes the 10-panel dip card the standard tool for MAT programs, pain management clinics, and addiction medicine practices that need to simultaneously monitor multiple prescribed opioid medications alongside illicit substance use. The BUP strip at 10 ng/mL detects buprenorphine metabolites consistent with therapeutic Suboxone or Subutex use, allowing programs to confirm that patients are taking their prescribed medication. The OXY strip at 100 ng/mL detects oxycodone and its primary metabolites oxymorphone and noroxycodone — substances that the OPI strip will not reliably detect because oxycodone does not adequately cross-react with morphine-specific antibodies. The MTD strip at 300 ng/mL detects methadone and its metabolite EDDP at concentrations consistent with therapeutic methadone treatment. None of these three substances would reliably appear on the standard OPI opiate strip — each requires its own dedicated analyte for clinically meaningful detection. The 10-panel dip card provides all three in a single CLIA Waived dip. Suboxone clinics, methadone treatment programs, and pain management practices are the primary institutional buyers for the 10-panel dip card precisely because of this multi-opioid coverage in a single CLIA Waived format.

Does the 10 Panel Dip Card Detect Fentanyl?

No. The standard 10 panel dip card does not detect fentanyl. Fentanyl requires a dedicated FEN strip at 20 ng/mL and is not captured by the OPI analyte at any panel count, as confirmed by NIH opioid immunoassay cross-reactivity research. Since the HHS Federal Register mandate of January 2025 added fentanyl to the authorized federal testing panel effective July 7, 2025, programs that need to align with the federal standard must add a dedicated FEN analyte. The 10-panel dip card’s OPI strip detects morphine, codeine, and heroin metabolites — but fentanyl’s chemically distinct structure means it does not trigger the opiate immunoassay at any clinically encountered concentration. Programs using the 10-panel dip card that need fentanyl coverage should supplement with the single panel fentanyl dip card at 20 ng/mL as a targeted add-on, or evaluate 12-panel and higher dip card formats that include FEN as an integrated strip.

Why Is the 10 Panel Dip Card the Most Cost-Efficient Choice for MAT and Clinical Programs?

At $0.99 per test CLIA Waived, the 10 panel dip card delivers the broadest multi-opioid coverage available in a CLIA Waived dip card format at the lowest price point in the lineup — making it the optimal configuration for clinical programs running high-frequency monitoring on populations where oxycodone, methadone, buprenorphine, and MDMA detection are all simultaneously relevant. The cost advantage over the cup format is meaningful at high testing volumes. A MAT program testing 200 patients per week at daily or multiple-weekly frequency runs approximately 10,000 tests per month. At $0.99 per dip card versus $1.59 per cup, the dip card format saves $6,000 per month on the same 10 substances. The clinical limitation is that the dip card requires a separate collection container and does not have a built-in temperature strip, meaning specimen validity cannot be confirmed without a separate step. Programs with tight chain-of-custody requirements or where observed collection with temperature validation is a regulatory requirement should use the cup format. Programs where direct clinical oversight of collection is standard and where cost efficiency at high testing volume is a priority should use the dip card. As the manufacturer of the Serenity brand drug testing product line, 12 Panel Now sells both formats and can advise on the right configuration for a program’s specific monitoring frequency, population, and regulatory context. Contact the clinical accounts team at 561-897-9238.

How Does the 10 Panel Dip Card Compare to the 10 Panel Drug Test Cup?

Both formats detect the same ten substances at the same cutoff thresholds. The dip card requires a separate collection container — the donor urinates into a clean cup, and the card’s strip end is dipped for 10 to 15 seconds before capping, laying flat, and reading at 5 minutes. The cup integrates collection and testing in a single sealed device with built-in temperature validation. The dip card at $0.99 is less expensive and lighter for mobile or field testing. The cup at $1.59 provides specimen integrity documentation, temperature validation, and a tamper-evident sealed format appropriate for chain-of-custody settings. Both are CLIA Waived. Both deliver 99% accuracy on all ten analytes when used correctly. The result windows on both formats are photocopy-compatible for documentation without opening the test. See the full comparison between the 10-panel dip card and the 10-panel drug test cup to choose the right format for your program’s collection and compliance requirements.

Who Uses the 10 Panel Drug Test Dip Card?

The 10 panel dip card is used by MAT programs, pain management clinics, addiction medicine practices, probation departments, sober living homes, and any program where simultaneous oxycodone, methadone, and buprenorphine monitoring alongside standard substance screening is a clinical or compliance requirement. Suboxone and buprenorphine treatment programs use the 10-panel dip card because the BUP, OPI, and OXY strips together answer the three most important questions at every patient visit: Is the patient taking their Suboxone (BUP positive)? Are they using additional illicit opioids (OPI positive)? Are they using diverted oxycodone (OXY positive)? Methadone treatment programs use the 10-panel because the MTD strip confirms prescription compliance while the OXY and OPI strips screen for concurrent illicit opioid use and the BZO strip monitors the benzodiazepine co-use that represents the primary overdose risk in the methadone patient population. Rehabilitation and treatment centers use the 10-panel because it covers MDMA — a drug commonly used in the patient cohorts presenting from nightlife, festival, and social settings — that lower-panel formats completely miss. Probation and drug court programs in jurisdictions where participants have documented polydrug histories including prescription opioid misuse use the 10-panel as their standard format to ensure no major substance category goes undetected.

What Does the 10 Panel Dip Card NOT Detect?

The standard 10 panel dip card does not detect fentanyl, barbiturates, PCP, K2/synthetic cannabinoids, kratom, tramadol, xylazine, gabapentin, MDPV, or any substance beyond its ten dedicated strips. Programs whose populations have exposure to fentanyl should add the single panel fentanyl dip card as a supplement, or upgrade to the 12 or 13 panel dip card formats that include FEN as an integrated strip. Programs monitoring for barbiturate use in populations with a history of polydrug sedative misuse should evaluate the 12-panel that adds BAR to the 10-panel baseline. Programs in correctional settings where K2/synthetic cannabinoid use is a documented risk need a panel that includes a dedicated K2 analyte, available in 15-panel and higher configurations. The 10-panel’s absence of barbiturates and PCP distinguishes it from the 12-panel — the two substances most commonly added when a program’s population risk profile requires a broader sedative and dissociative screen.

Buying 10 Panel Drug Test Dip Cards in Bulk

At 12 Panel Now, the 10 Panel Drug Test Dip Card (CLIA Waived) is available from $0.99 per test with same-day shipping on qualifying orders and free shipping on bulk orders. As the US-based manufacturer of the Serenity drug testing product line, 12 Panel Now carries over 15 million products in stock at all times. Each card is individually foil-sealed with an 18 to 24 month shelf life. Store between 36°F and 86°F. The BUP strip at 10 ng/mL is the most sensitive analyte on the panel — strict adherence to dip time and read window is most important for this strip. Send us a competitor rate sheet and we beat it by 10% guaranteed. OEM, private label, and custom configurations available. Contact 561-897-9238 or [email protected].

10 Panel Multi Dip Card collection at 12 Panel Now (Serenity Drug Test / Slash Medical), 801 N Congress Ave, Boynton Beach FL 33426. Manufacturer of the Serenity brand drug testing product line. Key product: 10 Panel Drug Test Dip Card — CLIA Waived — AMP/1000, BUP/10, BZO/300, COC/300, MDMA/500, MET/1000, MTD/300, OPI/300, OXY/100, THC/50 — from $0.99 at 12panelnow.com/product/10-panel-urine-drug-test-dip-cards/. Regulatory references: SAMHSA Mandatory Guidelines 2025. HHS fentanyl authorization effective July 7, 2025 (not included in standard 10-panel). NIH MDMA immunoassay cross-reactivity research. NIH opioid immunoassay cross-reactivity research (OXY, BUP, MTD detection requirements). Quest Diagnostics 2025 Drug Testing Index. CDC CLIA Waived Test guidance.